The Department of Pharmaceuticals is a central government department under the Ministry of Chemicals & Fertilizers, Government of India. Established on 1 July 2008 and headquartered in New Delhi, it operates schemes that support research, manufacturing and shared infrastructure for pharmaceuticals and medical devices. Its about page states that the department ensures the proper functioning of the central pharmaceutical undertakings under its control.
Support is delivered through separate government schemes, each with its own guidelines, eligibility rules and application route; the terms of one scheme do not carry over to another. Guidelines and call notices are published as PDF documents on the department's website, and eligibility conditions and ceilings sit in those guidelines rather than in summary pages. The schemes differ chiefly in the kind of support they give. The Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) is repayable, with a fixed percentage of net sales from each commercialised output paid back each year, and it sets separate conditions for early-stage projects. The medical device sub-schemes under the Scheme for Strengthening of the Medical Device Industry (SMDI) reimburse or part-fund specific costs, and the SMDI guidelines set its period as the financial years 2024-25 to 2026-27. The production-linked incentive (PLI) schemes for pharmaceuticals and for medical devices pay incentives tied to production, while the Scheme for Promotion of Bulk Drug Parks funds shared infrastructure for bulk drug units in parks.
Eligibility depends on the scheme. PRIP is open to startups holding a valid certificate from the Inter-Ministerial Board of Certification and to micro, small and medium enterprises holding a valid Udyam Registration Certificate. The pharmaceutical incentive is open to companies, partnerships, limited liability partnerships and proprietary firms registered in India that propose to manufacture eligible products, and it places applicants into groups by their global manufacturing revenue in the financial year 2019-20. The medical device incentive is open to companies registered in India. The clinical studies sub-scheme covers developers running clinical investigations or pre-clinical animal studies for a medical device, and the common facilities sub-scheme requires a special purpose vehicle with at least five medical device manufacturing units as members.
MISRID, the marginal investment sub-scheme of SMDI, aims to reduce import dependence by supporting the manufacture in India of key components, raw materials, finished devices and accessories. The Bulk Drug Parks scheme aims to set up bulk drug parks across the country, giving bulk drug units located in a park easy access to common infrastructure facilities, and three parks will be supported under it. The common facilities sub-scheme helps clusters of medical device makers set up shared equipment and testing facilities. The pages we could read do not state current call windows for most schemes, so their status is unclear from here. The SMDI marginal investment sub-scheme (MISRID) has closed: its June 2026 call notice gave a closing time of 6 PM on 23 July 2026, and a later notice gives 12 noon on 24 July 2026. Both fall in late July 2026, and the notices do not agree, so any date in a summary, including those on this page, should be treated as provisional until the call notice itself confirms it. The contact page gives an office at Room No. 340B, A-Wing, 3rd Floor, Shastri Bhawan, New Delhi, while the 2026 SMDI call notice names Kartavya Bhawan, New Delhi 110001 as its place; the two addresses differ, and the public pages do not say which one is current.